Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAS isolated hepatic arterial oxaliplatin infusion for colorectal liver metastases
ACTRN12617001268336Phase 2Recruiting
- Sponsor
- AllVascular
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin and capecitabine in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by AllVascular. Started Jan 2022; status: recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ACTRN12617001268336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001268336.